These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis. Cha SH; Kim K; Song YK Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334 [TBL] [Abstract][Full Text] [Related]
31. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics]. Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442 [No Abstract] [Full Text] [Related]
32. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F; Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665 [TBL] [Abstract][Full Text] [Related]
33. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib. Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e71-e73. PubMed ID: 29032022 [TBL] [Abstract][Full Text] [Related]
34. Targeted drugs in chronic myeloid leukemia. Gora-Tybor J; Robak T Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651 [TBL] [Abstract][Full Text] [Related]
36. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy. Breccia M; Chiodi F; Nardozza AP; Valsecchi D; Perrone V; Sangiorgi D; Giacomini E; Rendace MC; Coco P; Premoli E; Degli Esposti L Adv Ther; 2023 Mar; 40(3):961-974. PubMed ID: 36562943 [TBL] [Abstract][Full Text] [Related]
37. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I Cancer Sci; 2020 Oct; 111(10):3714-3725. PubMed ID: 33404088 [TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Jabbour E; Kantarjian H Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888 [TBL] [Abstract][Full Text] [Related]
39. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia. Sönmez Ö; Özgür Yurttaş N; İhtiyaroğlu İ; Çakır HM; Atlı Z; Elverdi T; Salihoğlu A; Seyahi N; Ar MC; Öngören Ş; Başlar Z; Soysal T; Eşkazan AE Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):232-239. PubMed ID: 38281820 [TBL] [Abstract][Full Text] [Related]
40. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory. Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]